Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
2014
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
2009
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Novel Controlled-Release Lemna -Derived IFN- α 2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial
2008
Video fluorescence microscopy studies of phospholipid vesicle fusion with a planar phospholipid membrane. Nature of membrane-membrane interactions and detection of release of contents.
1987
Therapeutic siRNA: state of the art
2020
Membrane curvature regulates the spatial distribution of bulky glycoproteins
2022 StandoutNobel
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq
2011 StandoutNobel
Treatment of kidney cancer
2009 StandoutNobel
Genome-wide Association of Hypoxia-inducible Factor (HIF)-1α and HIF-2α DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts
2009 StandoutNobel
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
1989
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
2014
ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
2011
A protein-conducting channel in the endoplasmic reticulum
1991 StandoutNobel
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Hypoxia and Inflammation
2011 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Lung cancer: New biological insights and recent therapeutic advances
2011
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
2014
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
2011
Pancreatic Adenocarcinoma
2014 Standout
Colorectal cancer
2019 Standout
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
2010
Chemotherapy Maintenance
2016
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids
2002
Progress in molecular-based management of differentiated thyroid cancer
2013
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
2012
Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery
1996
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
2012 Standout
EMT: 2016
2016 Standout
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
2011
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma
2012
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Effect of Blood-Brain Barrier and Blood-Tumor Barrier Modification on Central Nervous System Liposomal Uptake
1993
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
2018
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
2008
Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review
2017
Preparation of giant liposomes in physiological conditions and their characterization under an optical microscope
1996
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
2013
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Advanced and controlled drug delivery systems in clinical disease management
1996
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
2008
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
2011
Cancer of the Ovary
2004 Standout
Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review
2013
Lessons from Mouse Models of Thyroid Cancer
2009
Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances
2009
Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
2013
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Probing the Surface Structural Rearrangement of Hydrogels by Sum-Frequency Generation Spectroscopy
1998 StandoutNobel
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
1986
Polymeric Systems for Controlled Drug Release
1999 Standout
In vivoengineering of organs: The bone bioreactor
2005
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cyclodextrin Drug Carrier Systems
1998 Standout
The Pancreas Cancer Microenvironment
2012
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
2011
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
1999
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation
2015
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
2016
Review Hyperthermia and liposomes
1999
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
2014
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
2011
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
The Chemistry of Neutron Capture Therapy
1998 Standout
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Guidelines for the management of thyroid cancer
2014 Standout
First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up
2003
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Growth Factors, Matrices, and Forces Combine and Control Stem Cells
2009 StandoutScience
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
2014
Controlled release of cytarabine from poly(2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels
1997
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
2010
Clinical Translation of Nanomedicine
2015
Targeted therapy for advanced renal cell carcinoma
2008
Works of Sinil Kim being referenced
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
2008
Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
2011
Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study
2013
A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer
1994
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
2007
A slow-release methotrexate formulation for intrathecal chemotherapy
1993
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
2013
A Phase II Trial of Intraperitoneal High-Dose Carboplatin and Etoposide with Granulocyte Macrophage-Colony Stimulating Factor Support in Patients with Ovarian Carcinoma
1995
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
2016
Pharmacokinetics of an extended-release human interferon alpha-2b formulation
1993
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
2011
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
2008
Liposomes as Carriers of Cancer Chemotherapy
1993
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
2013
Soft tissue infection prophylaxis with gentamicin encapsulated in multivesicular liposomes
1995
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
2013
Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
1987
Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.
2012
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
1987
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
2011
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments
2014
Multivesicular liposomes containing cytarabine for slow-release Sc administration.
1987
Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients.
2012
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
2013
Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors
2015
Preparation of multivesicular liposomes
1983
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
2009
O-0026 Significant Relationship Between CA19-9 Kinetics and Overall Survival (OS) from a Phase 3 Trial in Advanced Pancreatic Cancer (APC).
2012
MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
2016
Preparation of cell-size unilamellar liposomes with high captured volume and defined size distribution
1981
Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
2011
Abstract CT327: Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection
2014
Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
2009